Eye drops containing a derivative of turmeric reduce the loss of retinal cells in rats, finds a new study led by UCL and Imperial College London researchers.
Loss of these cells is known to be an early sign of glaucoma and the eye drops could in time be a new treatment option for the condition.
In the new Scientific Reports paper, the researchers report a new method to deliver curcumin, extracted from the yellow spice turmeric, directly to the back of the eye using eye drops, overcoming the challenge of curcumin’s poor solubility.
They are also investigating how the eye drops could be used as a diagnostic tool for a range of conditions.
“Curcumin is an exciting compound that has shown promise at detecting and treating the neurodegeneration implicated in numerous eye and brain conditions from glaucoma to Alzheimer’s disease, so being able to administer it easily in eye drops may end up helping millions of people,” said the study’s lead author, Professor Francesca Cordeiro (UCL Institute of Ophthalmology, Western Eye Hospital and Imperial College London).
Glaucoma is a group of eye conditions affecting over 60 million people worldwide that leads to irreversible blindness in 1 in 10 cases. The condition mainly involves the loss of retinal ganglion cells, a type of neuron located near the surface of the retina. Stopping the loss of these cells early on has not yet been achieved, so it is a key focus of glaucoma research.
Curcumin has previously been shown to protect retinal ganglion cells when administered orally. For the current study, the researchers were seeking to find a more reliable method to deliver curcumin. Oral administration is difficult because curcumin has poor solubility, so it does not easily dissolve and get absorbed into the bloodstream, and would require people to take large amounts of tablets (up to 24 a day) that may cause gastrointestinal side effects.
The team developed a novel nanocarrier, wherein the curcumin is contained within a surfactant combined with a stabiliser, both of which are known to be safe for human use and are already in existing eye products. The nanocarrier can be used in eye drops to deliver much higher loads of curcumin than other products in development, increasing the drug’s solubility by a factor of almost 400,000, and localises the curcumin in the eyes instead of throughout the body.
The researchers initially tested the product on cells that are used to model glaucoma, before conducting trials in rats with eye conditions involving the loss of retinal ganglion cells.
After twice-daily use of eye drops in the rats for three weeks, retinal ganglion cell loss was significantly reduced compared to matched controls, and the treatment was found to be well-tolerated with no signs of eye irritation or inflammation.
Having found an effective way to deliver curcumin, the researchers are hopeful that it could also be used to diagnose Alzheimer’s disease, as curcumin is known to bind to the amyloid beta protein deposits implicated in Alzheimer’s, and can be detected in the retina with fluorescence to highlight the malignant proteins.
“We are now researching diagnostic uses for these eye drops alongside other ways to visualise the retina, as eye tests can be an opportunity to detect signs of neurodegeneration with a simple, non-invasive test,” said co-lead author Dr Ben Davis (UCL Institute of Ophthalmology and Imperial College London).
Professor Cordeiro added: “As we live longer, diseases such as glaucoma and Alzheimer’s are steadily increasing. We believe our findings could make a major contribution at helping the lives of people affected by these devastating diseases.”
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
- Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Saleson January 13, 2021 at 9:00 am
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma ...
- U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOPon January 13, 2021 at 4:00 am
The iStent infinite prospective, unmasked, multi-center, single-arm clinical trial enrolled subjects who had undergone prior unsuccessful incisional or cilioablative glaucoma surgery and had IOP not ...
- Focus on Eyes: Don’t let glaucoma steal your sighton January 12, 2021 at 4:06 am
Many people have glaucoma and don’t know it because the visual loss is gradual and mostly painless. Glaucoma is an eye disease that involves damage to the optic nerve, which connects the eye to brain.
- Glaucoma patients in Lothian face waits of up to 16 months as referrals exceed capacityon January 11, 2021 at 11:10 pm
Patients in Lothian are waiting up to 16 months to be treated for a common condition which is a leading cause of blindness among over-60s.
- Novel Anti-fibrotic Therapy for Glaucomaon January 8, 2021 at 5:00 am
A low molecular weight dextran-sulphate could play a key role in treating open angle glaucoma, a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible ...
- Research paves the way for new anti-fibrotic therapy for glaucomaon January 7, 2021 at 2:40 am
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB could play a key role in treating open angle glaucoma (OAG), a neurodegenerative ...
- Glaucoma is ‘sneak thief of sight’on January 5, 2021 at 11:06 pm
The month of January has been declared Glaucoma Awareness Month by Gov. Michelle Lujan Grisham. The governor’s proclamation encourages New Mexicans to be aware that glaucoma is the leading cause of ...
- Glaucoma does discriminate: What you need to know to protect yourselfon January 4, 2021 at 11:20 pm
Glaucoma is one of the leading causes of vision loss, affecting about 3 million people in the United States. But this potentially blinding eye disease does not affect all people equally. During ...
- Outlook on the Glaucoma Therapeutics Global Market to 2025 - Impact of COVID-19on December 31, 2020 at 9:45 am
Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global glaucoma therapeutics market grew at a CAGR of ...
via Bing News